Nichola Cooper

18.9k total citations · 5 hit papers
141 papers, 7.2k citations indexed

About

Nichola Cooper is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Nichola Cooper has authored 141 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Hematology, 54 papers in Genetics and 51 papers in Pathology and Forensic Medicine. Recurrent topics in Nichola Cooper's work include Platelet Disorders and Treatments (113 papers), Blood groups and transfusion (59 papers) and Autoimmune Bullous Skin Diseases (48 papers). Nichola Cooper is often cited by papers focused on Platelet Disorders and Treatments (113 papers), Blood groups and transfusion (59 papers) and Autoimmune Bullous Skin Diseases (48 papers). Nichola Cooper collaborates with scholars based in United Kingdom, United States and Italy. Nichola Cooper's co-authors include James B. Bussel, Roberto Stasi, Donald M. Arnold, Waleed Ghanima, Bertrand Godeau, Francesco Rodeghiero, Thomas Kühne, Sergio Amadori, Douglas B. Cines and Marc Michel and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Blood.

In The Last Decade

Nichola Cooper

129 papers receiving 7.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

2008 1.9k citations Roberto Stasi, Terry Gernsheimer et al. Blood profile →
American Society of Hematology 2019 guidelines for immune thrombocytopenia

2019 730 citations Cindy Neunert, Deirdra R. Terrell et al. Blood Advances profile →
Immune Thrombocytopenia

2019 285 citations Nichola Cooper, Waleed Ghanima profile →
Thrombopoietin receptor agonists: ten years later

2019 248 citations Waleed Ghanima, Nichola Cooper et al. profile →
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

2018 237 citations James B. Bussel, Donald M. Arnold et al. profile →

Peers

Countries citing papers authored by Nichola Cooper

Since Specialization

Citations

This map shows the geographic impact of Nichola Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nichola Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nichola Cooper more than expected).

Fields of papers citing papers by Nichola Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nichola Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nichola Cooper. The network helps show where Nichola Cooper may publish in the future.

Co-authorship network of co-authors of Nichola Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Nichola Cooper. A scholar is included among the top collaborators of Nichola Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nichola Cooper. Nichola Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK 2025 ·Journal of Market Access & Health Policy ·Nichola Cooper, Sı́lvia Stanisçuaski Guterres, (unknown), Koo Wilson, Sian James, Mondher Toumi, (unknown), Carly Rich, Daniel Eriksson	1
2	Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs 2025 ·Pediatric Blood & Cancer ·Joana Azevedo, (unknown), Cindy Neunert, Nichola Cooper, Rachael F. Grace	0
3	Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study 2024 ·Blood ·Nichola Cooper, David J. Kuter, Henrik Frederiksen, (unknown), (unknown), Wilma Barcellini, Joan Cid, Catherine M. Broome, (unknown), Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M. Risitano, Sangeeta Sawhney, Quentin A. Hill, Deepthi Jayawardene, (unknown), J. Zhao, Ahmed Daak	6
4	Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia 2024 ·Blood Advances ·David J. Kuter, Jiřı́ Mayer, (unknown), (unknown), Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Robert Bird, Jaromír Gumulec, Milan Košťál, Terry Gernsheimer, Waleed Ghanima, Ahmed Daak, Nichola Cooper	11
5	Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis 2024 ·Journal of Comparative Effectiveness Research ·Vera Bril, Johannes Lampe, Nichola Cooper, Peter Kießling, Ann Gardulf	3
6	Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension 2024 ·British Journal of Haematology ·Nichola Cooper, James B. Bussel, Maciej Kaźmierczak, Yoshitaka Miyakawa, (unknown), (unknown), Birgit Haier, (unknown), Puneet Kumar Singh, Rose Snipes, David J. Kuter	6
7	The role of genetics in refractory immune thrombocytopenia 2023 ·British Journal of Haematology ·James L. Zehnder, James B. Bussel, Nichola Cooper	1
8	European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia 2023 ·Platelets ·(unknown), Tomás José González‐López, Nichola Cooper, Francesco Zaja	3
9	P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR 2023 ·HemaSphere ·David J. Kuter, Nichola Cooper, (unknown), Ahmed Daak, Waleed Ghanima	0
10	Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia 2021 ·Advances in Therapy ·(unknown), (unknown), Laura Grant, Nichola Cooper, Donald M. Arnold, (unknown), Drew Provan, Adam Cuker, Quentin A. Hill, Yoshiaki Tomiyama, Waleed Ghanima	6
11	Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets 2021 ·Blood ·Alexander P. Bye, Willianne Hoepel, Joanne Mitchell, (unknown), Silvia Loureiro, Tanya Sage, Gestur Vidarsson, Jan Nouta, Manfred Wuhrer, (unknown), Marit J. van Gils, Neline Kriek, Nichola Cooper, Ian M. Jones, Jeroen den Dunnen, Jonathan M. Gibbins	67
12	A Patient’s Perspective on Impact of Immune Thrombocytopenia on Emotional Wellbeing: ITP World Impact Survey (I-WISh) 2020 ·Nichola Cooper	0
13	American Society of Hematology 2019 guidelines for immune thrombocytopenia breakdown → 2019 ·Blood Advances ·Cindy Neunert, Deirdra R. Terrell, Donald M. Arnold, George R. Buchanan, Douglas B. Cines, Nichola Cooper, Adam Cuker, Jenny M. Despotovic, James N. George, Rachael F. Grace, Thomas Kühne, David J. Kuter, Wendy Lim, Keith R. McCrae, Barbara Pruitt, (unknown), Sara K. Vesely	730
14	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia 2019 ·Blood ·David J. Kuter, Ralph V. Boccia, Eun‐Ju Lee, (unknown), Nikolay Tzvetkov, Jiřı́ Mayer, Marek Trněný, Milan Košťál, Roman Hájek, Vickie McDonald, (unknown), (unknown), (unknown), (unknown), Nichola Cooper	10
15	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial 2018 ·BMJ Open ·(unknown), Rosemary Greenwood, Jenny Ingram, (unknown), Ian Thomas, Rebecca Kandiyali, Andrew Mumford, Andrew D. Dick, Catherine Bagot, Nichola Cooper, Quentin A. Hill, Charlotte Bradbury	16
16	Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results 2017 ·Blood ·James B. Bussel, Donald M. Arnold, Nichola Cooper, Alhossain A. Khalafallah, Michael Boxer, Darla Liles, Waleed Ghanima, Keith R. McCrae, Hany Zayed, Benoît Cadieux, Anne‐Marie Duliège	2
17	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia 2012 ·Blood ·Vivek Patel, Matthieu Mahévas, Soo Yong Lee, Roberto Stasi, Susanna Cunningham–Rundles, Bertrand Godeau, Julie Kanter, Ellis J. Neufeld, Tillmann Taube, Ugo Ramenghi, Shalini Shenoy, Mary J. Ward, Nino Mihatov, (unknown), Philippe Bierling, Martin Lesser, Nichola Cooper, James B. Bussel	243
18	Migratory and Antigen Presentation Functions of IFN-Producing Killer Dendritic Cells 2009 ·Cancer Research ·Nourredine Himoudi, Mengyong Yan, Gerben Bouma, Daniel A. Morgenstern, Rebecca Wallace, (unknown), (unknown), Ayad Eddaoudi, (unknown), Nichola Cooper, John Anderson	11
19	Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab 2008 ·Blood ·Roberto Stasi, Nichola Cooper, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Elisabetta Abruzzese, Sergio Amadori	305
20	Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 2007 ·Blood ·Roberto Stasi, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, (unknown), Nichola Cooper, Sergio Amadori	231

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact